Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

  • Oncotutorial

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

  • Long Idea of the Year

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

  • Quickster: Update on Corbus

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. To see all of his column and his latest comments, go to his Stock Gumshoe page.] [Author’s note: This commentary has been […]

  • The 12 Biotechs of Christmas: Six

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

  • The 12 Biotechs of Christmas: Five

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

  • The 12 Biotechs of Christmas: Four

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

  • The Twelve Biotechs of Christmas: Two

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

  • Such A Pleasant Stay

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

  • Sea of Tranquility

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]

  • Tropic of Palatin

    [Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his thoughts and opinions are his own. His previous columns and recent comments can be found on his Stock Gumshoe page.] “He had never seen her body so abandoned, so unconscious […]

  • Ten Common Biotech Investing Mistakes

    [Ed. Note: Dr. KSS writes about medicine biotech stocks for the Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page for his past articles and most recent comments.] Assessing biotechnology stocks involves use of lots of mental microscopes and magnifying lenses. But the task […]

  • Quickster: T2 Biosystems ($TTOO)

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page to see his biography, latest comments and past articles.] About 18 months ago, I came across tiny Boston-area diagnostics start-up […]

  • The State of Things: Ruction at Regulus

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]

  • Recent Author Comments

    On Oncotutorial
    Yep, I feel the same way johnboy. The bigger problem is the parlous state of neuroscience. The transition point where hypothesis becomes theory is pretty iffy in science, but theories are more solid and most clinical trials are premised on them. In neurosc[...]
    On Oncotutorial
    Well, the earnest answer is that it takes a lot of education and training. I trained continuously in this stuff for 15 years after finishing college before I ever had a real job. It is stuff that can be learned but is hard to teach. I am a protein biochemi[...]
    On Oncotutorial
    Industry sponsored clinical trials need to get a lot more transparent: http://www.bmj.com/content/358/bmj.j3334 New in BMJ.[...]
    On Responses to Comments and a Proposed Study of Alcoholic Beverages
    Male and female livers are cardinally different: multiple studies of large cohorts of women, particularly in Scandinavia, suggest that among women, sustained daily consumption of more than one drink of alcohol is sufficient to lead to Laennec cirrhosis aft[...]
    On Oncotutorial
    I know. Good of you. All copacetic.[...]
    On Oncotutorial
    I think what smanuelm meant was approval of a development plan, ie, the FDA smiling on things. The agent is not approved-approved of course. But a momentous development for $CAPR and frankly, it probably will work in a trial well enough to fetch approval. [...]
    On Oncotutorial
    A line from the much-awaited, long-debated, double-gaited, variegated, never-sated and now promulgated Benitec quarterly report: "NATURE OF BUSINESS: N/A." And that sums it up. Tear yourself away! Woof![...]
    On Oncotutorial
    We've said it before: PD-1 checkpoint inhibitors ARE NOT created equal though they "seem" to act on the same pathway. Case in point: durvalumab ($AZN) bites the dust in lung cancer, with shares crumpling pre-market. Of the available checkpoint inhibitor[...]
    On Oncotutorial
    Regrettably NP now n $CAPR but will consider re-entering. To give some perspective, for years I have just howled at all the heavy weather and high dudgeon on Twitter over Sarepta and certain related companies over their approach to Duchenne. Not to sound c[...]
    On Oncotutorial
    Les Francais seront francais, I guess......[...]
    On Oncotutorial
    Sad but true and I agree. There's definitely a lot of posturing and Kabuki that goes on in biotech, and here occasionally too. Sometimes the cat drags in pumpers. All are welcome to bring their insight, instincts, feelings and biases to the table here for[...]
    On Oncotutorial
    Thanks for bringing it up Moriarty. Believe me I had meant to....so many things need covering. A good bottom line is this: I DO think tenapanor WILL get the blowing of white smoke from the FDA for both the renal and gut indication. Arguments that other age[...]
    On Oncotutorial
    Dept of You Don't See This Everyday: Director S. Papadopoulos buys on open market $910,000 worth of $RGLS shares.[...]
    On Oncotutorial
    Cptchiron: thanks for reading and posting. I began a commentary on this last night but dozed off around 2 am and didn't finish it. Will get some remarks together before end of day. My bottom line: truly, this is NOT the blow to $AKAO that anyone thought. T[...]
    On Oncotutorial
    John: you could well be right and what you did is not unsound in my view. I DO think the drug will find a clinical niche. Just don't know which one or when. The drug isn't bogus, and depression phase 2 may have been premised on too many soft assumptions ab[...]
    On Oncotutorial
    Let me tease out a point that Phil is making, and it's a good one. $AXSM is two stories: back pain, and depression. I've picked through what data they have and will be blunt: both stories are good, but the back pain story is much more solid. It is but one [...]
    On Oncotutorial
    Good question. Where $CUR ran aground was by bolting too many hypotheses together. Known: 189 can cause nerve regrowth in the CNS. Unknown: WHICH populations of nerves regrow. IS 189 indiscriminate or selective? Don't know because the MECHANISM BY WHICH IT[...]
    On Oncotutorial
    Hi gene: yes absolutely it can and should be used in combat situations. Norchi knows this, and intends to pursue it, but he's been appropriately secretive about whether they are negotiating with the military. As long as AC5 is sealed and aqueous, it doesn'[...]
    On Oncotutorial
    As a sidebar, it's worth noting that Glenn and I, from a late 2014 interaction with Terry Norchi, had the good fortune of seeing a now-censored corporate video of AC5 at work. Not that it matters, but it's interesting that AC5 is being spoken of a gel. In [...]
    On Oncotutorial
    Hi jking: the more things change the more they stay the same. In 1998, I was having lunch with Cynthia, a hepatology research coordinator at a school where I was on faculty. Cynthia was an extreme fitness advocate, and a paper had just been published makin[...]

    This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.